Black men develop heart failure at 39 on average. Five questions to ask your cardiologist about hypertensive heart disease.

In the CARDIA cohort, 27 young adults developed heart failure before age 50, 26 of them Black, at a mean onset age of 39, according to the 2009 NEJM paper by Bibbins-Domingo and colleagues. Three-quarters of those Black participants had clinical hypertension by age 40, and uncontrolled blood pressure in the decade before diagnosis was the dominant driver.

That finding reframed early-onset heart failure in Black men. It is not a mysterious ethnic risk. It is hypertensive heart disease, and it starts showing up in your 30s. The Multi-Ethnic Study of Atherosclerosis reported heart failure incidence of 4.6 per 1,000 person-years in African American participants versus 2.4 in white participants, and the 2008 Archives of Internal Medicine analysis showed that the disparity lost statistical significance once the models adjusted for hypertension and diabetes. The gap is the blood pressure.

This guide gives you five questions to bring to your next cardiology visit. Each one maps to a decision point in the 2022 AHA/ACC/HFSA Heart Failure Guideline where Black men have historically been undertreated. Write them down. Ask them.

1. What is my ejection fraction, and do I have HFrEF or HFpEF? Ejection fraction is the percentage of blood the left ventricle pumps out per beat. A normal reading is 50 to 70 percent. Heart failure with reduced ejection fraction (HFrEF) means 40 percent or lower; heart failure with preserved ejection fraction (HFpEF) means 50 percent or higher. The drug list is different for each, and your cardiologist should tell you which one you have and show you the number.

2. If I have HFrEF and I am still symptomatic on an ACE inhibitor, ARB, or ARNI plus a beta-blocker plus a mineralocorticoid receptor antagonist, am I a candidate for isosorbide dinitrate plus hydralazine? The A-HeFT trial enrolled 1,050 self-identified Black patients with moderate-to-severe heart failure and reported a 43 percent reduction in all-cause mortality on the combination, per Taylor and colleagues in NEJM, 2004. The 2022 AHA/ACC/HFSA guideline carries the combination as a Class I recommendation for Black patients with persistent NYHA Class III to IV symptoms on guideline-directed therapy. If nobody has raised it with you, raise it yourself.

3. Am I on an SGLT2 inhibitor? Dapagliflozin and empagliflozin reduce cardiovascular death and heart failure hospitalization in patients with HFrEF, and the 2022 guideline gives them a Class I recommendation alongside ACE inhibitor, ARB, or ARNI therapy, a beta-blocker, and a mineralocorticoid receptor antagonist. Studies of empagliflozin and dapagliflozin in HFpEF also support use across the ejection-fraction spectrum. Ask whether one is on your list and, if not, why not.

4. What is my home blood pressure target, and what has my recent average been? The CARDIA data tied early heart failure to years of uncontrolled hypertension, not a single clinic reading. A home monitor, cuff at heart level, twice in the morning, twice at night, over seven days, gives your cardiologist the average that actually predicts outcome. Ask for the number your cardiologist wants you under and how often to send the log.

5. Have I been evaluated for sleep apnea? Obstructive sleep apnea raises nocturnal blood pressure, worsens ventricular remodeling, and is underdiagnosed in Black men who snore or wake unrefreshed. A home sleep study is the usual first test. If your cardiologist has not asked about sleep, ask about sleep.

Bring your home blood pressure log, a current medication list with doses, and the dates of your last echocardiogram and ejection-fraction reading. Ask for your ejection-fraction number in writing. If any of the five questions above get a vague answer or no answer, request a second opinion from a heart failure cardiologist; the American College of Cardiology maintains a find-a-cardiologist tool, and our own Black provider directory has cardiologists who see patients in person and by telehealth.

If the answer to question 2 is that isosorbide dinitrate plus hydralazine has not been discussed and you are still symptomatic on the other three drug classes, ask specifically about A-HeFT and the 2022 guideline recommendation. Bring the PMID (15533851). Treatment decisions should cite a study your cardiologist can pull up in the room.